Two new drugs for the treatment of the skin condition psoriasis are now more affordable after the Government listed them on the PBS, Federal Member for Page Kevin Hogan said.
“Patients currently pay around $30,200 a year for Tremfya and $32,600 a year for Ilumya,” he said.
“Thanks to our investment, from next month the price drops for both treatments to just $40.30 per script, or $6.50 for concessional patients.
“Severe chronic plaque psoriasis is an inflammatory condition affecting the skin and nails.
“Psoriasis, which is a lifelong condition without a cure, can impact the emotional and social wellbeing of affected people.
“It can be associated with psychosocial issues including social isolation, poor self-image, depression and anxiety.
“This PBS listing was recommended by the independent Pharmaceutical Benefits Advisory Committee (PBAC).
“Our Government continues to list every drug on the PBS approved by the PBAC to ensure that new, essential medicines are affordable for all Australians.”
“We are now making on average one new or amended PBS listing every single day.
